News
Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of ...
The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...
"The Handmaid's Tale" may be coming to an end, but the world of Gilead is not with a sequel, "The Testaments," in production ...
Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...
Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...
WARNING: The following story contains spoilers about the fifth episode of The Handmaid's Tale's sixth and final season, ...
Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings ...
Oppenheimer lowered the firm’s price target on Gilead (GILD) to $125 from $132 and keeps an Outperform rating on the shares. The firm notes ...
Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...
The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback